Table 6

Linear regression for the decline in eGFR in the entire DHS cohort and in participants without and with prevalent diabetes according to SMg per 0.2 mg/dL decrease

Model 1Model 2Model 3Model 4Model 5
β95% CIP valueβ95% CIP valueβ95% CIP valueβ95% ClP valueβ95% CIP value
Entire cohort− 0.400.53 to -0.25<0.001− 0.340.49 to −0.19<0.001− 0.310.47 to −0.16<0.001− 0.30–0.44 to -0.14<0.001− 0.230.38 to -0.080.003
Without prevalent DM− 0.240.39 to −0.090.001− 0.220.37 to -0.060.008− 0.210.36 to −0.050.01− 0.18–0.34 to −0.020.02
With prevalent DM− 0.781.31 to -0.240.005− 0.581.16 to −0.0020.05− 0.601.20 to −0.010.05− 0.51–1.09 to 0.080.09
  • Model 1 was adjusted for age, gender, race/ethnicity, body mass index at DHS-1.

  • Model 2 was adjusted for variables in model 1 plus serum phosphorus, calcium, bicarbonate, albumin, intact parathyroid hormone, total cholesterol and high-density lipoprotein at DHS-1.

  • Model 3 was adjusted for variables in model 2 plus use of diuretics, dietary supplements, ACEI and ARB at DHS-1.

  • Model 4 was adjusted for variables in model 3 plus prevalent hypertension and CRP at DHS-1.

  • Model 5 was adjusted for variables in model 4 plus prevalent type 2 diabetes at DHS 1.

  • β, change in eGFR in reference to the highest quintile of SMg levels. eGFR was calculated according to the MDRD study equation. ΔeGFR was calculated as eGFR at DHS-2 minus eGFR at DHS-1.

  • ACEI, ACE inhibitors; ARB, angiotensin II receptor blockers; CRP, C reactive protein; DHS, Dallas Heart Study; DM, diabetes mellitus;  eGFR, estimated glomerular filtration rate; SMg, serum magnesium.